Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
Date:5/14/2009

ltimate goal of helping to improve the lives of patients."

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in more than 70 countries for the treatment of patients with liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including breast cancer, colorectal cancer, lung cancer, ovarian cancer, and as an adjuvant therapy for kidney cancer and liver cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common adverse events 20% related to Nexavar for both HCC and RCC were fatigue, weight loss, ra
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
2. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
3. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
4. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
5. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
6. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
9. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
10. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
11. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 Today the National ... of grants for the Brain Research through Advancing ... to develop and revolutionize new methods of understanding ... human brain. This first round of grants totaling ... was allocated to more than 100 investigators in ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:9/30/2014)... 30, 2014 Applying a well-known optical phenomenon ... Harvard University has demonstrated the ability to "paint" ... that holds promise for making future, flexible electronic ... sides of next-gen rocket ships and spacecraft with ... through oil in water, it becomes iridescent, revealing ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... the pro and cons of radio frequency identification technology ... at the second annual Wisconsin RFID Conference. Sponsored by ... at the steps for implementing RFID and predicted where ... about a product in an electronic tag. The tags ...
... MILWAUKEE - Metavante Corporation , a supplier of ... Corporation , has acquired two financial firms located in Virginia ... purchased GHR Systems , a provider of loan origination ... million and the deal is expected to close in the ...
... Wis. - It would be misleading to suggest that ... human embryos. They arent. In fact, no scientist in the ... ,It would also be disingenuous to suggest the process for ... at the outset -- from the process used in ...
Cached Biology Technology:Conference studies applications and lessons of RFID 2Conference studies applications and lessons of RFID 3The Attack of the Clones: No, its not a summer movie 2The Attack of the Clones: No, its not a summer movie 3
(Date:10/1/2014)... Reserve University researchers hope to take a healthy salad ... aggressive form of breast cancer in leafy greens. , ... the vaccine either by eating the salad or making ... assistant professor of biomedical engineering at Case Western Reserve ... The Susan G. Komen breast cancer organization is funding ...
(Date:10/1/2014)... 2014 Novel detection technology ... field  The life science field has ... the years. Some are shooting stars and others ... novel detection technology that has raised much enthusiasm ... technology is becoming commercially available. With their unique ...
(Date:9/30/2014)... visit the Mediterranean each year, but its deep-blue ... Earth. Almost 1,000 alien species, including fish, crustaceans, ... through human activities. In the open-access journal ... of researchers analyzed data from a new information ... how the introduction of alien species has changed ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2Biodiversity in the Mediterranean is threatened by alien species 2
... bacteria that break down pollutants do their job and ... toxic wastes. , Bacteria called Dehalococcoides ethenogenes, discovered in ... professor of civil and environmental engineering, and isolated and ... now in wide use to detoxify such carcinogenic chemicals ...
... announced the publication in the June 23 issue of the ... gene therapy trial for Parkinson’s disease and the first report ... for any adult neurodegenerative disease. , The open label ... disease demonstrated both a lack of adverse events related to ...
... in the United States and other northern mid- ... in offsetting global warming than previously thought, according ... The study, which sheds light on the so-called ... are removing an unexpectedly high proportion of carbon ...
Cached Biology News:Helping chlorine-eating bacteria clean up toxic waste 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4Scientists close in on missing carbon sink 2Scientists close in on missing carbon sink 3
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Biology Products: